BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 26688677)

  • 1. The Modern Landscape of Endocrine Therapy for Premenopausal Women with Breast Cancer.
    Rossi L; Pagani O
    Breast Care (Basel); 2015 Oct; 10(5):312-5. PubMed ID: 26688677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
    Bui KT; Willson ML; Goel S; Beith J; Goodwin A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal therapies in young breast cancer patients: when, what and for how long?
    Christinat A; Di Lascio S; Pagani O
    J Thorac Dis; 2013 Jun; 5 Suppl 1(Suppl 1):S36-46. PubMed ID: 23819026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
    Carlson RW; Henderson IC
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
    Montagna E; Cancello G; Colleoni M
    Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer.
    Pan K; Chlebowski RT
    Clin Breast Cancer; 2014 Jun; 14(3):147-53. PubMed ID: 24503025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases.
    Madeddu C; Gramignano G; Kotsonis P; Paribello F; Macciò A
    Oncol Lett; 2014 Sep; 8(3):1279-1282. PubMed ID: 25120706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers.
    Vaz-Luis I; Francis PA; Di Meglio A; Stearns V
    Am Soc Clin Oncol Educ Book; 2021 Mar; 41():1-15. PubMed ID: 33989019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women.
    Lu YS; Wong A; Kim HJ
    Front Oncol; 2021; 11():700722. PubMed ID: 34595110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal adjuvant endocrine therapy for early breast cancer.
    Stuart-Harris R; Davis A
    Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
    Azim HA; Davidson NE; Ruddy KJ
    Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Ovarian Function Suppression in Premenopausal Women with Early Breast Cancer.
    Park WC
    J Breast Cancer; 2016 Dec; 19(4):341-348. PubMed ID: 28053622
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.